Applied Biologics

Applied Biologics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Applied Biologics is a private, commercial-stage biotech company specializing in amniotic membrane-derived allografts for wound care and orthopedic applications. Founded in 2010/2012 and headquartered in San Diego with a state-of-the-art manufacturing facility in Scottsdale, Arizona, the company has vertically integrated operations from tissue recovery to product distribution. Its primary focus is on the XWRAP® product family, which is currently being evaluated in a pivotal multi-center randomized controlled trial for diabetic foot ulcers, with interim data published in 2025. The company positions itself on domestic manufacturing, high-quality standards, and clinical evidence generation.

Wound HealingOrthopedics

Technology Platform

Proprietary processing of minimally manipulated human amniotic membrane into dehydrated allografts for use as protective barriers and wound covers. The platform focuses on aseptic recovery and techniques to enhance handling, biodegradability, and prolonged performance.

Opportunities

The large and growing global advanced wound care market, driven by diabetes and an aging population, presents a significant opportunity.
Positive results from the ongoing pivotal trial could drive substantial adoption and reimbursement for XWRAP® in diabetic foot ulcers.
The 'Made in the USA' supply chain is a strong differentiator in a market sensitive to quality and reliability.

Risk Factors

The company faces clinical risk from its ongoing pivotal trial, where failure to meet endpoints would impede growth.
It operates in a highly competitive market with many similar amniotic membrane and advanced wound care products.
Reimbursement and market adoption for premium biologic products remain persistent challenges.

Competitive Landscape

Applied Biologics competes in the crowded amniotic membrane allograft and advanced wound care market against companies like Organogenesis (PuraPly®, Affinity), MiMedx (Epifix®, EpiCord), and Smith & Nephew, as well as numerous smaller tissue banks. Differentiation is based on proprietary processing, product formats, clinical evidence, and supply chain control.